Scripta Therapeutics raises £9m seed led by Oxford Science Enterprises and Apollo Health Ventures to upend conventional drug discovery

Scripta Therapeutics applies AI and experimental biology to map disease-driving transcription networks, aiming to identify new drug targets for neurodegenerative and complex conditions.